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Abstract
There have been previous reviews looking into the efficacy of vaccine candidates against
Zika infection in non-humans primates, but there hasn’t been a review looking into the efficacy
against Congenital Zika Syndrome (CZS).The aim of this project was to systematically review
literature on efficacy of vaccine candidates against Zika infection and CZS. A protocol was
developed following PRISMA guidelines. English articles published since 2015 were included.
Clinical trials (CCTs) that compared the efficacy of four Zika virus vaccine candidates' (PIV,
DNA, mRNA, and Adenovirus) against zika infection and CZS in human and non-human
primate models were included. Grey literature and studies with mice models were excluded.
Literature was searched from PubMed, Scopus, CINAHL and Cochrane Library and screened
against predetermined inclusion and exclusion criteria. Bias and quality of the studies was
assessed using the Effective Public Health Practice Project Quality Assessment Tool for
Quantitative Studies. Efficacy of the vaccine candidates was evaluated using two outcomes:
protection against Zika infection and whether CZS occurred. Studies were combined using a
meta-analysis technique to determine the summary estimates of the efficacy of the vaccine
candidates against Zika infection. All seven studies showed that the four vaccine types were
protective against Zika infection, and one study showed that a DNA vaccine was protective
against CZS. The meta-analysis found that the summary risk of Zika infection was 0.08 (0.01,
0.15) in vaccinated nonhuman primates versus unvaccinated. The development of a vaccine
aganst Zika infection has progressed quickly into clinical trials, but authorization of a vaccine
could falter because efficacy field trials are not currently possible. There still needs to be more
research into the disease mechanism of CZS before more vaccine efficacy studies occur.
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1. Introduction
1.1 What is Zika?
In 2016, the World Health Organization declared the Zika virus (ZIKV) to be a Public Health
Emergency of International Concern.1 Although Zika has been known since the mid 20th century,
it was not until 2015 that it began to affect the western hemisphere. Zika is a single strand RNA
virus in the flavivirus family along with Dengue, West Nile, and Yellow Fever. 2 The virus spread
by the vectors, Aedes aegypti and Aedes albopictus. The virus can also be sexually transmitted.
The virus can remain in the male urogenital tract for 90 days to 9 months post-infection.1
1.2 Clinical Features
The majority of infections are asymptomatic or have mild symptoms including fever, rash,
muscle, and joint pain.3 There has been evidence of Guillain-Barre syndrome being associated
with Zika infection in adults.4 When a pregnant woman becomes infected with ZIKA, it can
cause the fetus to be born with CZS or even result in preterm birth or miscarriage.3
There are several clinical features of CZS. First, CZS is cranial morphology with evidence of
fetal brain disruption sequence characterized by severe microcephaly and severe neurological
impairment.5 Another clinical feature of CZS are brain anomalies. Those seen in infants affected
by ZIKV were similar to another congenital disorder known as congenital cytomegalovirus
(CMV). However, there were marked differences between the two, specifically in the location of
calcifications. In CZS they are seen more in the subcortical region and in the periventricular in
CMV. In one study, 42 pregnant women suspected of having Zika had fetal imaging done and
found either calcifications or other central nervous system abnormalities.5 These abnormalities
are likely due to the way ZIKV targets neural progenitors. There are often ocular abnormalities
seen in those affected by CZS. One study found that infection in the first trimester significantly

correlated with ocular abnormalities.5 Finally, CZS is associated with congenital contractures
including clubfoot and arthrogryposis. The mechanism through which congenital contractures
occurs is still unknown, but it is thought to be due to ZIKV since it is not seen in other infants
with faciobrachial dystonic seizures (FBDS) but has occurred with intrauterine infections.5
1.3 Burden of Zika
From 2015 to 2018, there were 583,451 suspected cases and 223,477 confirmed cases of
ZIKV throughout North, Latin, and South America and Caribbean.6 In addition to the ZIKV
infection, there were a total of 3,720 confirmed cases of CZS, with an unknown number of
suspected cases.6 Several studies have been done looking at the aftermath of CZS. One study by
Franca and others collected data on 1,500 live born babies with microcephaly in Brazil.7 They
were able to categorize them based on the probability of the microcephaly being a result of CZS.
They found 76 definite cases, 54 highly probably cases, 181 moderately probable cases, 291
slightly probably cases, and had 899 discarded cases, cases that did not meet the clinical criteria
for microcephaly.7 They found that the mortality rate of the discarded cases was 14 per 1,000 and
was 51 per 1,000 for the probable and definite cases. 7
Another study done in Brazil looked at outcomes associated with microcephaly. The most
common were irritability (85%), pyramidal syndromes (56%), and epileptic seizures (50%).8
With pyramidal syndromes, the most notable symptoms is spasticity, which is a muscle control
disorder that is characterized by stiff muscles and hyperactive reflexes. They also found that 97%
had brain calcifications.8 Children with microcephaly require more time and care than children
without the condition. A qualitative study examined the effects on parents with children who
have microcephaly. Parents explained that they were unsure of how to properly care for their
child with microcephaly and that they would benefit from a workshop teaching them skills. They

also mentioned that some nurses were not comfortable vaccinating the child upon bringing in
their child for vaccinations.9 This study highlighted the need for both a vaccine and expanded
health services. Without a vaccine, more parents in these areas where Zika is endemic will live in
fear that their child will have CZS and that they may not be able to care for their child to their
best abilities.
1.4 Zika Vaccine Candidates
As of May 2020, there are 30 different vaccine candidates in Phase I in the preclinical phase,
with half still in the research phase.10 The vaccine candidates are different types, including
purified inactivated virus (PIV), DNA, Adenovirus (Ad), and mRNA.1 A review study published
in 2018 summarized the vaccines that are currently in clinical trials.1 Protection against ZIKV
was achieved via antibodies that bind the envelope of the virus (ENV). This has prompted
vaccine developers to focus on the ENV as the antigen of interest. Several of the vaccine types
currently in Phase 1 of clinical trials (PIV, DNA, and Ad) had 100% short-term protection but
with varying long-term protection in monkeys.1 The mRNA vaccines had 100% short-term
protection, but the study claimed that their long-term protection is still unknown in mice and
nonhuman primates.1 All four of these vaccine types have been able to induce neutralizing
antibodies in mice and nonhuman primate studies.1,11
1.5 Knowledge Gap and Rationale
Zika virus vaccine candidates examined so far showed promising levels of efficacy in mice
and non-human primate models.12 PIV, DNA, and Ad vaccines were capable of protecting from
Zika infection in rhesus monkeys.1 As of 2020, thirteen vaccines have moved into Phase 1 of
clinical trials, and one vaccine candidate has moved into Phase 2.12 The purpose of this review
was to summarize literature that compared the effectiveness of vaccines against Zika infection

and CZS based on non-human primate models instead of mice models to provide insight into
which vaccine may be the best choice. Mice models were excluded because they do have
different fetal development and placental structure than humans.10 Nonhuman primates can also
give more accurate insight into the dosage and administration of the vaccine candidates than
mice models.10
2. Methods
2.1 Eligibility Criteria
Randomized controlled trials (RCTs) or Controlled Clinical Trials (CCTs) that compared
Zika virus vaccine candidates' (PIV, DNA, mRNA, and Adenovirus) efficacy against CZS in
human and non-human primate trials were included. Articles published in English since 2015
were included. Articles were excluded based on the following criteria: grey or non-formally
published literature, articles not relevant to the topic, letters, abstracts only, reviews, articles
published in other languages, articles published prior to 2015, and mice models.
2.2 Outcomes
The primary outcome was whether there was protection against Zika infection. There was
protection if vaccinated subjects had no detectable viremia following the Zika challenge. The
secondary outcome was whether CZS occurs. Presence of CZS would be determined by the
presence of congenital deformities such as microcephaly.
2.3 Literature search and study selection
The following terms were used in searches of PubMed, CINAHL, Cochrane Library, and
Scopus databases: (“Zika Virus” OR “Congenital Zika Syndrome” OR Zika) AND (Vaccine OR
vaccination OR immunization). Additionally, article bibliographies were examined for potential
studies. After transferring the articles from the databases to EndNote, duplicates were removed

and then exported into Excel. Then, titles and abstracts were screened based on the inclusion and
exclusion criteria. Articles that were approved for full-text review were further screened based
exclusion/inclusion criteria and the availability of full-text data. Articles were included if they
addressed either the primary outcome (protection against Zika infection) or the secondary
outcome (protection against CZS). The article searches and screening processes were conducted
by a single author.
2.4 Data Extraction
Data was extracted from studies that met the predetermined eligibility criteria. The
following data was extracted: Author, study design, sample size, subjects in the study, vaccine
type, vaccination procedure, dosage, whether there was protection against Zika infection and/or
CZS, and row data from tables and figures that was used to calculate relative risk.
2.5 Quality and Bias Assessment
The Effective Public Health Practice Project (EPHPP) Quality Assessment tool was used
to assess both the quality of the studies, as well as any bias within the studies. 13 The tool looked
at six different domains: selection bias, study design, confounders, blinding, data collection
methods, and withdrawals or drop-outs.13 The purpose was to assist with the synthesis and
interpretation of the review’s results. The tool provides a guide for rating the individual domains
and the overall rating of the studies. Each component of the assessment tool given an individual
rating of 1 for “Strong”, 2 for “Moderate”, or 3 for “Weak.” Then a final score of the quality and
bias for each article was determined based on the score for each components of the tool. A study
was determined as strong quality if there were no weak ratings for all the six components, If
there were one weak ratings, the study was considered as a moderate quality. If there were two
or more weak ratings, the study was rated as weak quality.

2.6 Meta-Analysis
A random-effects model using the DerSimonian and Laird method was used to combine
the estimate the risk ratios of protection against Zika infection post vaccination from the
individual studies.14 We did post-hoc heterogeneity analysis and an evaluation of publication
bias. A funnel plot was produced to assess publication bias. The heterogeneity among the studies
was determined using the the inconsistency index I2, and statistical significance was assessed
using the cocrane Chi-square test. A funnel plot was used to evaluate publication bias and
statistical significance was evaluated using Egger’s regression test.
3. Results
3.1 Search Results and Selection Process
A total of 2,412 citations were found from PubMed, 2,012 from SCOPUS, 248 from
CINAHL, and 47 from Cochrane Library. After removing the duplicates, 3,315 unique citations
remained. Of the 3,315 articles, 3,295 articles were excluded due to either the title or the
abstract, not fitting eligibility criteria. Twenty articles were screened in full text, of which
thirteen were excluded due to incomplete data, missing full text, or failure to report on the
outcome of interest. Seven articles were selected to be included in the systematic review.

3.2 Description of studies
Four studies looked at PIV vaccines (Abbink, 2016; Dowd, 2016; Lecouturier, 2020;
Young, 2020), three studies tested DNA vaccines (Abbink, 2016; Luisi, 2020; Van Rompay,
2019), and only one study each looked at Ad vaccines (Abbink, 2016) and mRNA vaccines
(Pardi, 2017). The studies used Zika strain PRVABC59 or strain ZIKV-BR2015 as the challenge
strains. All seven studies used nonhuman primates, either rhesus macaques and cynomolgus
macaques.

Table 1. Overview of Included Studies

Vaccine
Type

Challenge
zika Strain

Abbink, 2016

DNA, PIV,
Adeno

ZIKV-BR2015,
PRVABC59

32

Yes

Dowd, 2016

PIV

PRVABC59

30

Yes

Lecouturier,
2020

PIV

PRVABC59

30

Yes

Luisi, 2020

DNA,
mRNA

PRVABC59

32

Yes

Pardi, 2017

mRNA

PRVABC59

11

Yes

Van Rompay,
2019

DNA

PRVABC59,
ZIKV-BR2015

30

Yes

Young, 2020

PIV

PRVABC59

35

Yes

Author/Year

Sample
Size

Were
vaccinated
participants
protected
from ZIKV
challenge?

Were
vaccinated
participants
Relative Risk protected
(95% CI)
from CZS?
0.0210
(0.00130.3268)
0.0417
(0.00610.2838)
0.0283
(0.00180.4402)
0.0833
(0.02210.3141)
0.0897
(0.00631.2853)
0.0274
(0.00180.4227)
0.2333
(0.12200.4464)

Relative Risk
(CI)2

NA

NA

NA

NA

NA

NA

NA

NA

NA

Yes

NA
0.0374
(0.00250.5708)

NA

NA

3.3 Study Findings
The primary outcome for this review was protection against Zika challenge postvaccination. All seven studies evaluated vaccine protection against Zika infection.15-21 The study
done by Abbink, et al. investigated the protective efficacy of three vaccine types: DNA, PIV, and
Ad. All three had the same dosage (5mg) with 8 rhesus macaques per group.16 The DNA and PIV
vaccines were administered to the macaques on weeks 0 and 4. The Ad and placebo vaccines
were administered on week 0.15
The PIV vaccine group and 8 controls were challenged with PRVABC59 or ZIKV-BR2015
(4/group) to assess vaccine protection.15 All 8 in the PIV group were protected against both
challenge strains. All the controls experienced increased viral load, with no difference between
the two strains.15 The DNA and Ad vaccine groups were challenged with ZIKV-BR2015.16
Neutralizing antibodies were induced in both vaccine groups, although it occurred on week 2 for
the Ad group versus week 6 in the DNA group. Both were determined to be protective against
Zika challenge.15
The study carried out by Dowd et. al in 2016 compared the efficacy of two different DNA
vaccines: VRC5288 and VRC5283. There were two different dosages, with 6 rhesus macaques
per group.16 The first was 4 mg on weeks 4 and 0. The second was 1 mg on weeks 0 and 4. There
was an additional group of 6 that received a placebo.16 They were challenged with PRVABC59.6
All animals that received two doses of 4mg of VRC5283, 1mg of VRC5283, or 4mg of
VRC5288 were protected from Zika challenge.16 One animal that received two 4 mg doses of
VRC5288 had detectable viral load and was considered not protected.16 The viral load was
significantly lower than that seen in the control animals. In total, twenty-three of the twenty-four
that received either of the two vaccines were protected.16

The study done by Lecouturier et. al was the only study to use cynomolgus macaques
rather than rhesus macaques. It tested the effectiveness of different dosages of their secondgeneration PIV (SP-PIV) vaccine compared to the first-generation of the PIV vaccine and a
placebo.17 There were 5 groups with 6 participants each. The first group was the 1st gen PIV
vaccine at 1mg, SP-PIV at 1mg, SP-PIV at 2mg, SP-PIV at 4mg, and then the control group.17
Vaccines were administered on weeks 0 and 4 for all groups. Those that received 1mg of SP-PIV
also received a booster after 6 months.17 This group was not challenged. All 18 cynomolgus
macaques that were vaccinated with either the 1st generation PIV or SP-PIV and then challenged
PRVABC59 were all protected.17
The study done by Luisi et. al looked at the protective efficacy of a DNA self-amplifying
messenger RNA, and a self-amplifying messenger DNA vaccine. There were four groups, with 8
rhesus macaques per group: a) 75 microgram DNA, b) 75 microgram SAM-RNA, c) 4mg SAMDNA, and d) control group.18 Group A was vaccinated on weeks 0 and 5, group B on weeks 0
and 6, group C on weeks 0 and 7, and group D on weeks 0 and 4.18 The animals were challenged
with PRVABC59 and then tested neutralizing antibodies. All of the vaccinated animals were
protected by their respective vaccines.18
The study by Pardi, et. al was investigating the protection of an mRNA vaccine against
Zika infection using rhesus macaques.19 The goal was to determine if a low dosage would still be
effective against Zika infection.219 This study had three dosages. Group 1 vaccinated 1
participant with 600 micrograms of mRNA vaccine; Group 2 vaccinate 1 participant with 200
micrograms of mRNA vaccine; and Group 3 vaccinated 3 participants with 50 micrograms of
mRNA vaccine.19 Group 4 served as the control group, with 6 participants. All of the groups

were given a single dose at week 0 and then challenged with PRVABC59.19 All 5 of the
vaccinated primates were protected against the Zika challenge.19
The study by Van Rompay, et.al was the only study to look at both protection against
Zika infection and CZS.20 The study focused on a DNA vaccine (VRC5283). Eighteen rhesus
macaques were vaccinated with two 1 mg doses at weeks 0 and 4.20 Once immunized, the
participants were bred. Only thirteen of the treatment group conceived. The groups and controls
were exposed to PRVABC59 twice and ZIKV-BR2015 once during their pregnancy.20 The
authors tested for neutralizing antibodies in the mother and determined that there was protection
against the Zika challenge.20
The study carried out by Young et. al in 2020 compared the efficacy of different dosages
of a PIV vaccine.21 There were six groups, with 6 rhesus macaques per group. Treatment groups
were 2 doses of 1) 0.016 micrograms, 2) 0.08 micrograms, 3) 0.4 micrograms, 4) 2 micrograms,
5) 10 micrograms, and 6) the control group.21 Animals were immunized at weeks 0 and 4 and
then challenged on day 71 with PRVABC59.21 All the animals in dosage groups 3, 4, and 5 were
protected from Zika infection. Only three animals from group 2 and two animals in group 1 were
protected. All of the controls were infected with Zika.21
The secondary outcome for this review was the presence of CZS post-vaccination. Only
one study tested whether their vaccine of interest protected fetuses from CZS.20 While eighteen
macaques were immunized, only thirteen became pregnant.20 Only 10 controls were used, with
two losing the fetus due to complications unrelated to Zika infection.20 In order to more
accurately model exposure in the wild, the animals were challenged with Zika virus three times,
twice with PRVABC59 and once with ZIKV-BR2015.20 The fetus was tested to determine if
there were any congenital disabilities such as microcephaly as well as for Zika RNA.20 They

determined that there were no fetal defects present, there was no Zika RNA detected, and that all
thirteen fetuses were protected from CZS.20
3.4 Meta-Analysis and Publication Bias Results
There was zero-heterogeneity among the studies included in this review (I2=0, p=0.616).
The summary relative risk estimate of Zika infection in those vaccinated was 0.08 (0.01, 0.15)
compared to those who were unvaccinated. This value was significant.
Figure 1. Forest plot

The plot shown below shows six of the seven studies lying to the left of the center line,
suggesting there is publication bias. The Egger’s test for the asymmetry of the funnel plot was
also significant (bias= -0.202, p=0.004).

Figure 2. Funnel Plot

3.5 Quality and Bias Assessment Results
The quality and bias of the included studies were evaluated using the EPHPP Quality
Assessment tool. A summary of the results for each domain is shown in Table 2 and Appendix A
Table 1. All the studies were rated as “moderate” or “strong” quality in selecting the stuy
participants , study design, confounders, and data collection methods (Table 2). None of the
studies stated that they were randomized except for the one done by Abbink and others in 2016.
Abbink did not state the method of randomization. Similarly, only three studies- Lecouturier,
2020; Luisi, 2020; and Pardi, 2017- explicitly stated that the outcome assessors were blinded to
the vaccination status of the study participants. For the others, it was unclear if they were blinded
or not since it was not mentioned in their methods. Since the study participants were non-human

primates, it was not necessary for them to be blinded. Overall, the quality of the studies was
moderate, with low bias.
Table 2. Quality and Bias Assessment of Included Articles

Author,
Year

Selection Study
Bias
Design

Confounders

Blinding

Data Collection
Methods

Withdrawal
& Dropouts

Final
Rating

Abbink,
2016
Dowd, 2016

2

1

1

1

1

2

1

2

1

1

1

1

1

2

Lecouturier,
2020
Luisi, 2020

2

1

1

2

1

1

2

2

1

1

2

1

1

2

Pardi, 2017

2

1

1

2

1

1

2

Van
Rompay,
2019
Young, 2020

2

1

1

1

1

1

1

2

1

1

2

1

1

1

Key
1=Strong
2=Moderate
3=Weak

4. Discussion
4.1 Summary and Public Health Implications
This review included 7 controlled trials in non-human primates studying the efficacy of
four different vaccine types against Zika infection. All seven trials had different vaccines
dosages and dosage schedules but were all able to protect non-human primates against Zika. The
study by VanRompay found that a DNA vaccine provided protection against CZS, with a relative

risk of 0.04 (0.03, 0.57).20 Compared to the previous review on Zika vaccine candidates, this
review found additional studies showing vaccine candidate efficacy against Zika infection. This
review also added to the relatively sparse literature on vaccine candidate efficacy against CZS. It
also provided additional evidence with a meta-analysis. Based on a combined analysis of the
seven studies using a meta-analysis technique, the summary relative risk of Zika infection in
those vaccinated was 0.08 (0.01, 0.15) compared to those who were unvaccinated. This review
can aid in policy surrounding research into a vaccine candidate effective against Zika infection
and CZS. The path to authorization of a vaccine is still uncertain, but needs to occur before the
next outbreak occurs. This review could serve as evidence needed for different paths to
authorization of a vaccine.
4.2 Strengths and Limitations
There were some strengths and limitations to this review. One strength to this review was
the broad search terms used. These yielded a high number of articles, and likely captured the
majority of the articles related to this topic. Another strength was that the meta-analysis found
that the pooled risk of Zika infection in the vaccinated versus unvaccinated was 0.08.
One limitation was that there were a large number of studies and only a single reviewer.
Studies that fit the criteria of the review were likely missed during the title and abstract screening
process. Another limitation was the presence of publication bias. Those intending to produce a
vaccine likely will not publish a study if it will make their product look bad. And a third
limitation is that there are still few studies assessing the efficacy of vaccines against CZS in nonhuman primates. One explanation for the lack of vaccine candidate efficacy studies against CZS
using nonhuman primates is that there is no consensus about how Zika causes CZS.22 However,

there are numerous studies focusing on nonhuman primates as models for CZS and attempting to
determine specifics behind the disease mechanism.
4.3 Challenges and Approaches to Future Research
Currently, several PIV, DNA, mRNA, and Ad vaccines that have proceeded human trials,
either Phase 1 or 2, studying safety, tolerability, and immunogenicity. The next step would be
Phase 3 field efficacy trials, which would not be possible with the low number of cases right
now.23 These field efficacy trials would include randomized trials in different areas with disease
transmission, which allow an estimate of vaccine efficacy.23 There are two possible approaches
to solving the problem of low incidence of cases.
The first option is the “Accelerated” pathway. Usually this applies to serious or lifethreatening illnesses, which means Zika infection on its own would not qualify.24 However, with
the serious complications associated with CZS, it would be possible to pursue the accelerated
pathway for Zika vaccines.24 To qualify, there would need to be a “reasonably likely” surrogate
endpoint to predict clinical benefit.24 Under the traditional pathway, the clinical endpoint would
be protection against Zika infection, but under the animal rule, antibody titers could serve as a
surrogate endpoint.24
The second is utilizing the “Animal Rule”. This is a rule that is set by the FDA to
authorize medicines or vaccines using animal trial data.23 Similar to the accelerated pathway,
there would need to be a strong immune marker to bridge the animal and human data, such as
neutralizing antibodies.24 In order to use the animal rule, there would need to be well designed
animal studies using an appropriate animal model. As mentioned earlier, nonhuman primate
models would be better than mice because nonhuman primates have placental structure and
immune reponse that is similar to humans.10 The nonhuman primate studies included in this

review could provide the evidence to determine what would be an appropriate antibody titer.
However, currently Zika does not qualify for the animal rule while the accelerated pathway is
still an option.24
The third, and least likely, option is Controlled Human Infection Models (CHIM).24 In
2016, NIAID and Walter Reed Army Institute of Research determined that Zika CHIM were not
ethical.23 However, this was during the epidemic and since then, a CHIM may be ethically
justifiable since the traditional pathway may not be possible. CHIMs would require methods to
prevent the spread of Zika to non-participants, which would include excluding females of a
reproductive age and the mandatory usage of highly effective contraception.23 CHIMs would
only be applicable to a vaccine against Zika infection, and would not be possible to use to test
efficacy of a vaccine that prevents CZS. This would likely be a last resort if the Accerlerated
pathway or Animal Rule cannot be used or applied.
4.4 Conclusion
Due to the unpredictability of the next outbreak of Zika, the development of a safe and
effective vaccine that can protect against Zika infection and CZS remains important, especially
in endemic areas where there is still a risk of CZS. This review found that the vaccine candidates
were effective against Zika infection in nonhuman primates, with a relative risk of 0.08 (0.01,
0.15). Moving forward, there should be research into the disease mechanism of CZS using nonhuman primates. Before there is confirmation, or at least consensus, about how CZS occurs,
there likely will not be more progress into a vaccine that protects against CZS. On the other
hand, vaccine candidates against Zika infection are progressing quickly into clinical trials. The
next step would be deciding how to authorize a Zika vaccine without field efficacy trials before
the next outbreak.
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Appendix A
Table A.1. Full Quality and Bias Assessment Results of Included Studies

Domain
Are the
individuals
selected to
participate in
the study likely
to be
representative
of the target
population?
What
percentage of
selected
individuals
agreed to
participate?
Selection
Bias

Abbink Dowd201
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6
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20
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1

1
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2

2

2

2

2
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2
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Study Design

2

2

2

2

2

2

2

Was the study
described as
randomized?
Was the
method of
randomization
described?
If not
described as
randomized,
was the
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appropriate?
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No

No

No

No

No

No

No

No

No

No

No

No
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1
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differences
between the
groups prior to
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percentage of
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controlled for
in the design
or analysis.
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reported in
terms of
numbers
and/or reasons
per group?
Indicate the
percentage of
participants
completing the
study. (If the
percentage
differs by
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the lowest.)
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